Amid complaints about unilateral drug company restrictions on the 340B drug pricing program and mounting pressure from industry-backed advocates for even more 340B changes to favor drugmakers, a bipartisan group of six U.S. senators have taken a proactive step by asking for ideas to ensure “stability” for 340B. This move came in the form of a request for information (RFI) … [Read more...]
Recapping a Momentous Year for 340B
Dec. 31, 2021– Today is the final day of what might be one of the most eventful years in the history of the 340B drug pricing program. Key developments in the 340B world stood out even amid all the news about a global pandemic, a change in leadership in Washington, and an uneasy economic climate. As we wrap up 2021 and look forward to a new year, we are reflecting on some of … [Read more...]
Drug Industry Report on 340B Attempts a Diversion from Unlawful Manufacturer Actions
October 14, 2020— A new report from the drug industry consultant Berkeley Research Group (BRG) takes aim at community-based pharmacies in the 340B drug pricing program. The report implies, without evidence, that for-profit pharmacy chains are making excessive profits on these arrangements. It ignores the fact that these partnerships provide critical funding for safety-net and … [Read more...]
Drug companies answer scrutiny with more lobbying dollars
May 2, 2019— With its pricing practices under a congressional microscope, the pharmaceutical industry’s top trade group spent nearly $10 million on lobbying expenditures in the first three months of this year. That figure is on top of additional millions spent by some of the individual companies that have received the most attention recently in the drug pricing … [Read more...]
Drug Prices Continue to Soar and the Public Notices
March 27, 2018—A trio of new reports out this past week indicates that the historic rise in prescription drug prices in the U.S. continues and the American public is concerned. First, a report by Axios found the prices of the top 20 drugs prescribed in the U.S. rose by more than 200 percent in the past 14 months. Based on an analysis by Pharmacy Benefits Consultants, Axios … [Read more...]
Senate Hearing Next Week on Outrageous Prescription Drug Prices
December 5, 2017—The Senate Health, Education, Labor and Pensions (HELP) Committee is holding a Dec. 12 hearing on new National Academies of Sciences (NAS) findings on why medicines cost so much and recommendations on how to fix the problem. The NAS’s Nov. 30 report is drawing attention for calling on the federal government to negotiate drugs prices with manufacturers, deny … [Read more...]
Judge Orders Dec. 21 Hearing in Suit to Block Huge Cuts to 340B Hospitals
November 28, 2017—A federal district judge has scheduled a Dec. 21 hearing in the lawsuit seeking to stop drastic Medicare Part B drug reimbursement cuts for many 340B hospitals from taking effect on Jan. 1. … [Read more...]